文献速递垂体与肾上腺疾病

转录因子ASCL1作为库欣病治疗的新潜在靶点

Transcription Factor ASCL1 Acts as a Novel Potential Therapeutic Target for the Treatment of the Cushing's Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究采用多组学方法,结合RNA测序与Sanger测序描绘库欣病不同基因突变背景下的转录失调,发现ASCL1在USP8突变型和野生型肿瘤中特异性过表达,可促进促肾上腺皮质激素过量分泌和肿瘤发生,ASCL1抑制剂在AtT-20细胞和原代库欣病细胞中显示疗效,ASCL1过表达与患者更大肿瘤体积和更高促肾上腺皮质激素分泌相关。

要点

  • ASCL1在USP8突变型和野生型库欣病肿瘤中特异性过表达。
  • Ascl1在AtT-20细胞中直接调控Pomc并促进促肾上腺皮质激素过量分泌和肿瘤发生。
  • ASCL1抑制剂在AtT-20细胞和原代库欣病细胞中显示疗效。

核心结论

  • 研究结果有助于阐明库欣病的发病机制,并提示ASCL1是库欣病治疗的潜在靶点。

研究设计与样本

  • 多组学研究,结合RNA测序与Sanger测序,并在体外研究ASCL1功能,在68例库欣病患者中评估ASCL1的临床相关性。

主要发现

  • ASCL1仅在USP8突变型和野生型肿瘤中过表达。
  • Ascl1促进促肾上腺皮质激素过量分泌和肿瘤发生,并在AtT-20细胞中直接调控Pomc。
  • ASCL1抑制剂在AtT-20细胞和原代库欣病细胞中均显示有前景的疗效。
  • ASCL1过表达与库欣病患者更大的肿瘤体积和更高的促肾上腺皮质激素分泌相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pathogenesis of Cushing's disease (CD) is still not adequately understood despite the identification of somatic driver mutations in USP8, BRAF, and USP48. In this multiomics study, we combined RNA sequencing (RNA-seq) with Sanger sequencing to depict transcriptional dysregulation under different gene mutation backgrounds. Furthermore, we evaluated the potential of achaete-scute complex homolog 1 (ASCL1), a pioneer transcription factor, as a novel therapeutic target for treatment of CD and its possible downstream pathway. METHODS: RNA-seq was adopted to investigate the gene expression profile of CD, and Sanger sequencing was adopted to detect gene mutations. Bioinformatics analysis was used to depict transcriptional dysregulation under different gene mutation backgrounds. The function of ASCL1 in hormone secretion, cell proliferation, and apoptosis were studied in vitro. The effectiveness of an ASCL1 inhibitor was evaluated in primary CD cells, and the clinical relevance of ASCL1 was examined in 68 patients with CD. RNA-seq in AtT-20 cells on Ascl1 knockdown combined with published chromatin immunoprecipitation sequencing data and dual luciferase assays were used to explore downstream pathways. RESULTS: ASCL1 was exclusively overexpressed in USP8-mutant and wild-type tumors. Ascl1 promoted adrenocorticotrophin hormone overproduction and tumorigenesis and directly regulated Pomc in AtT-20 cells. An ASCL1 inhibitor presented promising efficacy in both AtT-20 and primary CD cells. ASCL1 overexpression was associated with a larger tumor volume and higher adrenocorticotrophin secretion in patients with CD. CONCLUSION: Our findings help to clarify the pathogenesis of CD and suggest that ASCL1 is a potential therapeutic target the treatment of CD. SUMMARY: The pathogenesis of Cushing's disease (CD) is still not adequately understood despite the identification of somatic driver mutations in USP8, BRAF, and USP48. Moreover, few effective medical therapies are currently available for the treatment of CD. Here, using a multiomics approach, we first report the aberrant overexpression of the transcription factor gene ASCL1 in USP8-mutant and wild-type tumors of CD. Ascl1 promoted adrenocorticotrophin hormone overproduction and tumorigenesis and directly regulated Pomc in mouse AtT-20 cells. Notably, an ASCL1 inhibitor presented promising efficacy in both AtT-20 and primary CD cells. Importantly, ASCL1 overexpression was associated with a larger tumor volume and higher adrenocorticotrophin secretion in patients with CD. Thus, our findings improve understanding of CD pathogenesis and suggest that ASCL1 is a potential therapeutic target the treatment of CD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen Z, Jia Q, Zhao Z, et al. Transcription Factor ASCL1 Acts as a Novel Potential Therapeutic Target for the Treatment of the Cushing's Disease. J Clin Endocrinol Metab. 2022. PMID: 35521682. doi:10.1210/clinem/dgac280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。